Article

Therapeutic siRNA silencing in inflammatory monocytes

Center for Systems Biology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Nature Biotechnology (Impact Factor: 39.08). 11/2011; 29(11):1005-10. DOI: 10.1038/nbt.1989
Source: PubMed

ABSTRACT Excessive and prolonged activity of inflammatory monocytes is a hallmark of many diseases with an inflammatory component. In such conditions, precise targeting of these cells could be therapeutically beneficial while sparing many essential functions of the innate immune system, thus limiting unwanted effects. Inflammatory monocytes-but not the noninflammatory subset-depend on the chemokine receptor CCR2 for localization to injured tissue. Here we present an optimized lipid nanoparticle and a CCR2-silencing short interfering RNA that, when administered systemically in mice, show rapid blood clearance, accumulate in spleen and bone marrow, and localize to monocytes. Efficient degradation of CCR2 mRNA in monocytes prevents their accumulation in sites of inflammation. Specifically, the treatment attenuates their number in atherosclerotic plaques, reduces infarct size after coronary artery occlusion, prolongs normoglycemia in diabetic mice after pancreatic islet transplantation, and results in reduced tumor volumes and lower numbers of tumor-associated macrophages.

1 Follower
 · 
256 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: The development of cancer has been an extensively researched topic over the past few decades. Although greatstrides have been made in cancer prevention, diagnosis,and treatment, there is still much to be learned about cancer'smicro-environmental mechanisms that contribute tocancer formation and aggressiveness. Macrophages, lymphocy teswhich originate from monocytes, are involved inthe inflammatory response and often dispersed to areas ofinfection to fight harmful antigens and mutated cells intissues. Macrophages have a plethora of roles includingtissue development and repair, immune system functions,and inflammation. We discuss various pathways by whichmacrophages get activated, various approaches that canregulate the function of macrophages, and how these approachescan be helpful in developing new cancer therapies.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Despite the advances that have been made in developing new therapeutics, cardiovascular disease remains the leading cause of worldwide mortality. Therefore, understanding the mechanisms underlying cardiovascular tissue injury and repair is of prime importance. Following cardiac tissue injury, the immune system has an important and complex role in driving both the acute inflammatory response and the regenerative response. This Review summarizes the role of the immune system in cardiovascular disease - focusing on the idea that the immune system evolved to promote tissue homeostasis following injury and/or infection, and that the inherent cost of this evolutionary development is unwanted inflammatory damage.
    Nature Reviews Immunology 01/2015; 15(2):117-29. DOI:10.1038/nri3800
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Delayed M1 toward M2 macrophage phenotype transition is considered one of the major causes for the impaired healing after myocardial infarction (MI). While searching for molecules that modulate M1 and M2 macrophage polarization, we identified collapsin response mediator protein-2 (CRMP2) as a novel molecule involved in macrophage polarization to M1. In this study, we evaluated the effect of silencing CRMP2 on macrophage polarization, inflammation and fibrosis post myocardial infarction. CRMP2 expression was assessed with Western blotting or immunohistochemistry. Macrophage phenotypes were measured with flow cytometry, quantitative real-time PCR (qPCR), Western blotting or immunohistochemistry. CRMP2 siRNA was delivered into the macrophages infiltrated in the wound of ApoE(-/-) mice through lipidoid nanoparticle, and fibrosis, leukocyte infiltration and inflammation parameters were measured with qPCR. Infarct size was measured with Masson's trichrome staining. Echocardiography was performed to assess ventricular systolic dimension, left ventricular diastolic dimension, anterior wall thickness and posterior wall thickness. Student's t-test (for 2 groups) and ANOVA (for > 2 groups) were used for statistical analyses. CRMP2 was expressed in a higher level in M1 macrophages than M2 subsets, and CRMP2 RNA interference (RNAi) resulted in a switch of bone marrow-derived macrophages from M1 to M2 phenotype. High level of CRMP2 was also observed in the macrophages infiltrated in the infarct area 3 days post MI in both wildtype (WT) and ApoE(-/-) mice, and the expression of CRMP2 retained in the infiltrated macrophages of ApoE(-/-) mice but not in that of WT mice 10 days after MI. Nanoparticle-mediated delivery of CRMP2 siRNA to ApoE(-/-) mice with MI resulted in dramatic switch of wound macrophages from M1 to M2 phenotype, marked decrease in inflammation and fibrosis, and significant attenuation of post-MI heart failure and mortality. CRMP2 is highly expressed in M1 macrophages and silencing CRMP2 reprograms macrophage phenotype and improves infarct healing in atherosclerotic mice.
    Journal of Inflammation 12/2015; 12(1):11. DOI:10.1186/s12950-015-0053-8 · 2.22 Impact Factor

Full-text (2 Sources)

Download
195 Downloads
Available from
Jun 10, 2014